Whole blood clotting time (CT) testing measures the interval required for freshly drawn blood to form a stable fibrin clot, providing a global evaluation of the intrinsic coagulation pathway. The test is widely used for initial screening of coagulation disorders, point-of-care monitoring of high-dose heparin during cardiac surgery and extracorporeal circulation, and hemocompatibility assessment of blood-contacting medical devices in accordance with ISO 10993-4. This article explains the technical principles, sample requirements, test methods, reference ranges, and typical applications of whole blood clotting time testing.
Technical Overview
Whole blood clotting time (CT), also known as the coagulation time, is defined as the interval between the withdrawal of blood from the vascular system and the formation of a visible, stable fibrin clot under controlled conditions, typically at 37 °C. First systematized by Lee and White in 1913, the test evaluates the combined performance of the intrinsic coagulation pathway (factors XII, XI, IX, and VIII) and the common pathway (factors X, V, II, and fibrinogen), together with the influence of blood contact activation on foreign surfaces.
Because clotting time responds to severe deficiencies of intrinsic-pathway factors, circulating anticoagulants such as heparin, hypofibrinogenemia, and certain hypercoagulable states, it has historically served as a first-line screening test. However, the method is relatively insensitive to mild or moderate factor deficiencies and is highly dependent on pre-analytical variables, which is why plasma-based assays such as APTT and PT have largely replaced the classical CT in routine clinical laboratories.
Whole blood clotting time nevertheless retains an important role in modern practice. The activated clotting time (ACT), a contact-accelerated variant, is the standard point-of-care assay for monitoring high-dose heparin during cardiopulmonary bypass, ECMO, and interventional procedures. In addition, clotting time measurements form part of the coagulation test category defined in ISO 10993-4 and GB/T 16886.4 for evaluating interactions between medical devices and blood.
- Temperature control at 37 °C and the use of consistent tube dimensions and materials (glass, plastic, or siliconized surfaces)
- Ratio of blood volume to contact surface area
- Quality of venipuncture and avoidance of tissue thromboplastin contamination
- Timing technique, such as tilting frequency, and operator proficiency
- Interval between blood collection and testing, typically within one to two minutes for direct clotting time methods
Testing Samples
Fresh Non-Anticoagulated Whole Blood
Classical clotting time testing is performed on freshly drawn venous blood collected without anticoagulant. A clean, rapid venipuncture is essential; the first few milliliters, which may contain tissue thromboplastin, are usually discarded using a two-syringe technique, and testing must begin immediately to prevent premature clot formation in the collection device.
Citrated Whole Blood or Platelet-Rich Plasma
For recalcification-based assays, blood is anticoagulated with 3.2% (0.109 mol/L) trisodium citrate at a 9:1 blood-to-anticoagulant ratio, consistent with CLSI guidance on coagulation specimen handling. Citrated samples allow controlled re-initiation of coagulation by adding calcium chloride and permit parallel platelet function and coagulation assays on the same specimen.
Blood for Activated Clotting Time Testing
ACT testing uses fresh, non-anticoagulated blood drawn directly into cartridges or tubes containing a contact activator such as celite, kaolin, glass beads, or diatomaceous earth. The sample is analyzed immediately at the point of care without intermediate processing.
Animal Blood for Medical Device Evaluation
Under ISO 10993-4 and GB/T 16886.4, in vitro thrombogenicity and clotting time studies may be performed with human donor blood or with blood from animal species such as rabbit, ovine, porcine, or canine sources, selected to reflect the intended use of the device. Species, donor health status, anticoagulant type and concentration, and the time from collection to testing must be documented and scientifically justified.
Testing Items
Depending on the purpose of the study, a whole blood clotting time evaluation may include the following test items:
- Whole blood clotting time by the Lee-White glass tube method
- Clotting time in siliconized or plastic tubes with low contact activation
- Capillary tube and slide clotting time for rapid screening
- Activated clotting time at baseline and under heparinized conditions
- Recalcification time of citrated whole blood or platelet-rich plasma
- Material-induced clotting time shifts and thrombus formation in device contact models
Typical reference intervals vary by method: approximately 3–7 minutes for the capillary method, 5–12 minutes for the Lee-White glass tube method, and 15–30 minutes for the siliconized tube method, while baseline ACT values generally fall between 90 and 140 seconds. Each laboratory should establish and validate method-specific reference ranges for its own conditions.
Testing Methods
Lee-White Test Tube Method
One milliliter of freshly drawn blood is transferred to a clean glass tube maintained at 37 °C. The tube is tilted at regular intervals, typically every 30 seconds, without agitation or foaming, until the blood no longer flows when the tube is inverted. The elapsed time from blood entry into the tube until clot formation is recorded as the clotting time. Running duplicate or triplicate tubes started sequentially reduces timing error.
Siliconized Tube Method
This procedure is identical to the Lee-White method except that the interior surface of the tube is siliconized to suppress factor XII contact activation. Because surface-mediated activation is minimized, the clotting time is longer and the method is more sensitive to mild coagulation defects and to circulating heparin.
Capillary Tube Method
A glass capillary is filled with blood from a standardized fingertip puncture. At fixed intervals, a short segment of the capillary is gently broken, and the endpoint is reached when a fibrin thread appears between the broken ends. The method is rapid and requires minimal equipment, but its reproducibility is limited.
Slide Method
A drop of blood is placed on a clean glass slide and, at 30-second intervals, a needle tip is dipped into the drop and slowly lifted. The appearance of a fibrin strand between the needle and the surface marks the endpoint. This approach is a crude screening technique and is rarely recommended for formal evaluation due to high variability.
Activated Clotting Time (ACT)
Fresh whole blood is added to a cartridge or tube containing a contact activator, and automated point-of-care analyzers detect clot formation using optical, mechanical, or electromechanical sensors, reporting results within roughly 90–180 seconds. ACT is the reference point-of-care test for managing high-dose unfractionated heparin during cardiopulmonary bypass, where therapeutic targets commonly range from 400 to 600 seconds depending on protocol, as well as during ECMO, vascular interventions, and hemodialysis, and for verifying heparin neutralization with protamine.
Recalcification Time Method
Citrated whole blood or platelet-rich plasma is brought to 37 °C and recalcified with a defined volume of calcium chloride, after which the time to clot formation is measured. Because pre-analytical variables such as citrate ratio, hematocrit, and temperature are controlled, the recalcification time is more reproducible than the direct clotting time and is frequently preferred in biomaterial and pharmacological studies.
In Vitro Thrombogenicity Assessment (ISO 10993-4)
For blood-contacting devices and materials such as catheters, stents, oxygenators, vascular grafts, and extracorporeal tubing, clotting time is measured after controlled exposure of citrated or heparinized blood to the test article in comparison with negative and positive reference materials. Endpoints include clotting time shift, gravimetric thrombus mass, and biomarkers of coagulation activation such as prothrombin fragment F1+2, thrombin-antithrombin complexes, and D-dimer. ASTM F2382 provides a standardized approach for assessing the inherent thrombogenicity of materials. Such studies are typically conducted by accredited third-party laboratories under documented quality management systems to support regulatory submissions.
Applications
Whole blood clotting time testing supports both clinical diagnostic objectives and product development programs across several domains:
- Initial screening for coagulation disorders, including hemophilia A and B, factor XI deficiency, von Willebrand disease, hypofibrinogenemia, and monitoring of disseminated intravascular coagulation trends
- Point-of-care monitoring of unfractionated heparin during cardiac surgery, ECMO, interventional cardiology, and hemodialysis, including confirmation of protamine reversal
- Hemocompatibility evaluation of blood-contacting medical devices under ISO 10993-4 and GB/T 16886.4 for regulatory submissions
- Characterization of anticoagulant, procoagulant, and surface-modified biomaterial candidates during pharmaceutical and medical device research and development
- Quality control and batch release support for blood-contacting consumables such as extracorporeal tubing sets, reservoirs, and coated components
In routine clinical diagnostics, the classical clotting time has largely been superseded by APTT and PT because of their superior sensitivity and standardization. Whole blood methods remain indispensable, however, wherever plasma-based assays are impractical, particularly at the point of care and in extracorporeal circulation settings where heparin concentrations exceed the measurable range of APTT.
FAQ
What is the normal range of whole blood clotting time?
Typical values are 3–7 minutes by the capillary method, 5–12 minutes by the Lee-White glass tube method, and 15–30 minutes using siliconized tubes, while baseline ACT generally falls between 90 and 140 seconds. Ranges differ between methods and laboratories, and locally validated reference intervals should always be applied.
What causes a prolonged clotting time?
Prolongation is observed in hemophilia and other severe intrinsic pathway factor deficiencies, von Willebrand disease, hypofibrinogenemia and afibrinogenemia, disseminated intravascular coagulation, significant liver dysfunction, circulating anticoagulants, and heparin therapy. Pre-analytical errors such as tissue thromboplastin contamination, delayed testing, or inadequate temperature control can also extend the result.
What causes a shortened clotting time?
Shortening may occur in hypercoagulable states, the early hypercoagulable phase of disseminated intravascular coagulation, and conditions associated with increased thrombin generation. Isolated mild shortening is often clinically nonspecific and should be interpreted alongside other coagulation data.
How does the activated clotting time differ from the classical clotting time?
ACT incorporates a contact activator that accelerates coagulation, shortening the assay to a few minutes and making it suitable for bedside monitoring of high-dose heparin. The classical clotting time does not use an activator, takes longer to complete, and reflects unaccelerated intrinsic pathway coagulation.
Which standards govern clotting time testing for medical devices?
ISO 10993-4, mirrored nationally by GB/T 16886.4, classifies coagulation testing as one of the principal hemocompatibility categories and specifies endpoints covering thrombosis, coagulation, platelets, hematology, and the complement system. ASTM F2382 addresses inherent material thrombogenicity, and CLSI guidelines cover specimen collection and handling for coagulation assays. Manufacturers typically engage accredited third-party laboratories to perform these studies for regulatory submission.
Why has clinical use of the classical clotting time declined?
The test shows limited sensitivity to mild factor deficiencies, strong dependence on operator technique and pre-analytical conditions, and relatively long turnaround times. Plasma-based APTT and PT assays provide better standardization and diagnostic information, so they have replaced the classical clotting time for routine screening, while ACT remains essential in high-dose heparin management.